Anti-SCUBE1 antibody having high internalization capacity in leukemia
Publish time: 2023-03-17 00:00:00
Anti-SCUBE1 antibody having high internalization capacity in leukemia
Docket Number
12A-1110526
IP Status
US Provisional Application
Abstract
SCUBE1 is the founding member of the SCUBE (signal peptide-CUB-EGF-like repeat-containing protein) family membrane anchorage protein. SCUBE1 is highly expressed on membrane of acute myeloid leukemia (AML) cells and critical for its survival and proliferation. The present invention relates to a method for the use of an anti-SCUBE1 antibody-drug conjugate for killing SCUBE1-expressing AML cells.
Technological Advantages
- The antibody could be used to target and treat AML having SCUBE1 expression.
- The antibody is highly specific and has internalization capacity.
- The antibody could be used by pharmaceutical companies to produce antibody-drug conjugate.
Applications of Technology
- SCUBE1 on the plasma membrane of MLL-r leukemia cells is a potential target for immunotherapy as shown by the strong anticancer activity of an anti-SCUBE1 ADC in MLL-AF9 leukemias.
- In addition, because SCUBE1 is a direct target gene of HOXA9 and because HOXA9 is dysregulated in a number of leukemic genetic alterations apart from MLL-translocations, NUP98-fusion, surface SCUBE1 might be an ideal therapeutic target for a broader spectrum of hematological malignancies including FLT3-ITD AML and acute lymphocytic leukemia (ALL).
Inventor
Ruey-Bing (Ray) Yang
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Anti-SCUBE1 antibody having high internalization capacity in leukemia